Pharmafile Logo
Pharmafocus logo
Advanced Search

lymphoma

Showing 15 posts of 31 posts found.

takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News
kymriah

Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

February 1, 2019
Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …

News
shutterstock_212035546

Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold

August 3, 2018
Medical Communications, Research and Development Epizyme, FDA, lymphoma, pharma, tazemetostat

Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead …

News
celgene_building

Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma

July 24, 2018
Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma

Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …

News
shutterstock_159488225

Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

December 13, 2017
Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …

News
800px-cancer_cells_1

New research reports first-ever response of central nervous tumour to CAR T therapy

August 29, 2017
Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals

Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …

News

Roche antibody becomes first of its kind authorised for blood cancer

July 26, 2017
Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche

NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News
celltrion1

Celltrion biosimilar proves effectiveness in lymphoma and rheumatoid arthritis

June 14, 2017
Research and Development Cellltrion, Truxima, biosimilar, lymphoma, rheumatoid arthritis, rutiximab

Celltrion Healthcare has revealed new data which validates its biosimilar Truxima (CT-P10) as non-inferior to its reference product rituximab in …

News

Gamida Cell receives Breakthrough Therapy Designation from FDA

October 12, 2016
Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma

Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …

News
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016
Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …

News
takeda_tokyo_hq

Phase III success for Takeda in lymphoma drug

August 1, 2016
Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma

Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …

News
celgene_1_02

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016
Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …

News
roche__tree

Roche’s lymphoma drug fails to beat rivals in Phase III trial

July 18, 2016
Research and Development, Sales and Marketing Roche, lymphoma, phase III

Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …

News
takeda_world

Takeda says its cancer drug Adcetris gets European backing in for hodgkin lymphoma

July 6, 2016
Research and Development European Commission, Takeda, drug trial, lymphoma

Takeda Pharmaceutical (TSE: 4502) said the European Commission has extended the marketing authorization for its Adcetris (brentuximab vedotin) to treat …

News

Blood cancer drug Adcetris approved by FDA

August 24, 2011
Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma

The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024